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ABSTRACT 
Rational & Objective: Data on outcomes of patients with end-stage renal disease (ESRD) 
secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) is 
limited. We examined the incidence and prevalence of ESRD due to scleroderma in Europe, 
and the outcomes among these patients following initiation of RRT. 
Study Design: Registry study of incidence and prevalence, and a matched cohort study of 
clinical outcomes. 
Setting & Participants: Patients represented in any of 19 renal registries that provided data 
to the ERA-EDTA Registry between 2002-2013.  
Predictor: Scleroderma as the identified cause of ESRD.  
Outcomes: Incidence and prevalence of ESRD from scleroderma. Recovery from RRT 
dependence, patient survival after ESRD, and graft survival after kidney transplantation.  
Analytic approach: Incidence and prevalence were calculated using population data from the 
European Union and standardised to population characteristics in 2005. Patient and graft 
survival were compared to two age- and sex-matched control groups without scleroderma: 1) 
diabetes mellitus (DM) as the cause of ESRD and 2) conditions other than DM as the cause of 
ESRD. Survival analyses were performed using Kaplan Meier analysis and Cox regression.  
Results: 342 patients with scleroderma (0.14% of all incident RRT patients) were included. 
Between 2002 and 2013, the range of adjusted annual incidence and prevalence rates of RRT 
for ESRD due to scleroderma were 0.11-0.26 and 0.73-0.95 per million population, 
respectively. Recovery of independent renal function was greatest in the scleroderma group 
(7.6% vs. 0.6% in diabetes and 2.1% in other-PRDs, both P<0.001), though time required to 
achieve recovery was longer. The 5-year survival probability from day 91 of RRT among 
patients with scleroderma was 38.9% (95% confidence interval (CI), 32.0%-45.8%) while 
their 5-year post-transplantation patient survival and 5-year allograft survival were 88.2% 
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(95% CI, 75.3%-94.6%) and 72.4% (95%CI, 55.0%-84.0%), respectively. The adjusted 
mortality from day 91 on RRT was higher among patients with scleroderma than observed in 
both control groups (hazard ratio: 1.25, 95%CI:1.05-1.48, and 2.00 95%CI=1.69-2.39). In 
contrast, patient and graft survival after kidney transplantation did not differ between patients 
with scleroderma and control groups.  
Limitations: No data on extra-renal manifestations, treatment, or recurrence. 
Conclusions: Survival of patients with scleroderma who receive dialysis for more than 90 
days was worse than for those with other causes of ESRD. Patient survival after 
transplantation was similar to that observed among patients with ESRD due to other 
conditions. Patients with scleroderma had higher rate of renal function recovery sufficient to 
stop RRT than controls. 
 
Index words: incidence, dialysis, end-stage renal disease, outcomes, scleroderma, kidney 
transplantation 
 
Nontechnical Summary: Scleroderma is a rare chronic connective tissue disease with multi-
organ involvement. There are limited published data on the outcomes of patients with end-
stage renal disease (ESRD) secondary to scleroderma requiring renal replacement therapy 
(RRT); i.e. dialysis or kidney transplantation. In this European study we examined the 
incidence, prevalence of ESRD due to scleroderma and the clinical outcomes of 342 patients 
who received RRT for ESRD due to scleroderma between 2002 and 2013. We compared 
these outcomes to matched controls who either developed ESRD with a diagnosis of diabetes 
mellitus or with any other diagnosis except diabetes mellitus or scleroderma. Patients with 
scleroderma receiving RRT had a higher rate of recovering kidney function sufficiently to 
permit stopping RRT than observed in the matched control groups, though their overall 
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survival was worse. Transplanted patients with scleroderma showed similar survival to the 
matched-controls, supporting the practice of kidney transplantation in these patients.  
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INTRODUCTION 
Systemic sclerosis (also referred to as scleroderma) is a rare chronic connective tissue 
disease with multi-organ involvement characterized by immune activation, vasculopathy, 
fibroblast dysfunction, and excessive collagen accumulation in the skin and internal organs 
[1-3].  
Renal disease in patients with scleroderma, particularly scleroderma renal crisis, 
results in significant morbidity and mortality [1]. Scleroderma renal crisis typically manifests 
with an acute onset of accelerated hypertension, rapidly progressive renal failure, frequently 
accompanied by microangiopathic haemolytic anaemia and thrombocytopenia. Occurring in 
approximately 3-10% of the scleroderma population, severe renal disease is commonly seen 
in patients with diffuse rather than limited cutaneous scleroderma [1, 4]. Until the 1970s, 
scleroderma renal crisis was recognized as the main cause of death in patients with 
scleroderma, though since the introduction of treatment with ACE inhibitors and reduction of 
corticosteroid doses the prognosis has substantially improved [4]. Nevertheless, about 25-50% 
of patients with scleroderma renal crisis will develop end-stage renal disease (ESRD) and the 
mortality associated with this condition remains high [1, 3-7].  
There is limited knowledge regarding the prevalence of scleroderma renal crisis 
requiring renal replacement therapy (RRT) [8] and due to the infrequency of this condition 
there are a limited number of large multicentre or registry-based studies available [3-7, 9-11]. 
While the outcome of patients with scleroderma on dialysis seems to be uniformly worse than 
that of patients with other causes of ESRD [7, 11], the outcomes of kidney transplantation are 
less clear. It is known that renal function may recover after commencing RRT and there is an 
ongoing discussion regarding the optimal timing of kidney transplantation in patients with 
scleroderma [5, 12, 13].  
We analysed the trends in incidence and prevalence of RRT for ESRD due to 
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scleroderma in the European Renal Association - European Dialysis and Transplant 
Association (ERA-EDTA) Registry and determined the patient characteristics, patient 
survival on RRT, patient and graft survival after kidney transplantation, and causes of death in 
a large cohort of European patients initiating RRT between 2002 and 2013.  
METHODS 
Patients and data collection 
The ERA-EDTA Registry collects data annually on patients starting RRT from 
national and regional renal registries in Europe. Renal registries sending individual patient 
level data to the ERA-EDTA Registry between 2002 and 2013, with at least 50% percent 
coverage of the general population were included in the study. The renal registries included 
were Austria, Dutch-speaking Belgium, French-speaking Belgium, Denmark, Finland, 
Greece, Iceland, the Netherlands, Norway, the Spanish regional renal registries of Andalusia, 
Aragon, Asturias, Basque Country, Cantabria, Castile and León, Catalonia, and Valencia, 
Sweden, United Kingdom: England, Northern Ireland and Wales, and United Kingdom: 
Scotland. The details of methods of data collection and data processing are described 
elsewhere [14]. The cause of death was defined and categorized according to the ERA-EDTA 
coding system [14]. All national and regional registries contributing data to the ERA-EDTA 
Registry followed national legislation with regard to ethics committee approval. Additional 
informed patient consent was not required for this study due to the de-identified nature of the 
information obtained. 
Cases and matched control groups 
The incidence, prevalence and patient survival on RRT analyses refer to patients 
starting RRT for ESRD due to “systemic sclerosis (scleroderma)” (ERA-EDTA primary renal 
disease [PRD] code 87 [14]), as recorded by the responsible physician. Patient and graft 
survival after kidney transplantation refer to all patients with a diagnosis of scleroderma, or 
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the matched controls (described below) who received their first kidney-only transplant 
between 1st January 2002 and 31st December 2013. This included patients who commenced 
RRT for ESRD before 2002. Age and sex were compared between scleroderma and non-
scleroderma patients. We then formed two matched control groups of patients without 
scleroderma: 1) diabetes mellitus as a primary renal disease (PRD codes 80 and 81); and 2) 
patients without scleroderma and without diabetes mellitus as a primary renal disease, 
referred to as ‘other PRDs’. Due to the low number of scleroderma patients, we matched 10 
controls to 1 case. We matched on age group at the start of RRT (5-year age groups) and sex, 
when comparing patients receiving RRT. When comparing transplant recipients we matched 
on age group at the time of kidney transplantation (5-year age groups) and sex.  
Statistical analysis 
Time trends in the incidence of RRT per million population (pmp) were studied by 
year according to the date of RRT onset for all participating European countries/regions 
combined. Incidence was then assessed by country/region for the whole study period. Time 
trends in the prevalence of RRT pmp by year, defined as the number of patients alive and 
receiving RRT on 31st December of that year, divided by the mid-year general population, 
were studied for all participating European countries/regions. Incidence and prevalence rates 
were adjusted for age and sex using the European Standard Population of 2005 as a reference 
[15]. The time trends for the incidence rates and prevalence were estimated using Poisson 
regression, with the observed rate as the outcome and the year as the explanatory variable. 
The mean percentage annual change (MPAC) and its 95% confidence interval were computed 
from each model as [exp(β)−1] × 100, where β denotes the regression coefficient of time (i.e., 
change in the event rate per year). To examine whether the trends were linear, we performed 
Joinpoint regression analysis. Joinpoint regression allows the identification of points in time 
where a significant change in the linear slope of a trend occurs. The analysis starts with zero 
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joinpoints (i.e. a straight line) and then tests whether one or more joinpoints are significantly 
different and must be added to the model [16]. This was performed using the Joinpoint 
software (version 4.0.4) [17].  
To compare the characteristics of scleroderma patients receiving RRT with each of the 
matched control groups separately, the Wilcoxon signed-rank test was used for continuous 
variables with a skewed distribution, and the McNemar square test for categorical variables. 
A two-tailed p-value <0.05 was considered as statistically significant. The first treatment 
modality was defined as treatment at day 91 after the start of RRT, as some patients received 
haemodialysis (HD) for a short period, while preparations were made for peritoneal dialysis 
(PD).  
The Kaplan-Meier method and Cox regression analysis were used for the survival 
analyses. Patient survival on RRT was examined for individuals who initiated RRT for ESRD 
due to scleroderma between 2002 and 2013, and was compared with each of the matched 
control groups separately. Day 91 after the onset of RRT was taken as the starting point for 
these survival analyses. The death of the patient was the event studied. Follow-up time was 
censored at recovery from RRT dependence, loss to follow-up, and the end of the follow-up 
period (31st December 2013). Within the Cox regression analysis we took the strata (matched 
groups) into account. Patient  survival on RRT was adjusted for time period (with three 
intervals, 2002-2005, 2006-2009 and 2010-2013) and country. Patient and graft survival after 
kidney transplantation was examined for patients who received their first transplant between 
2002 and 2013 (regardless of the RRT start date). The scleroderma group was compared with 
each of the matched control groups separately. In these analyses the date of the first kidney 
transplant was defined as the first day of follow-up. For patient survival after transplantation, 
the event studied was death, and in case of graft survival, the events were graft failure and 
death. Reasons for censoring were loss to follow-up and the end of follow-up period (31st 
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December 2013). In the Cox regression analysis, patient and graft survival were adjusted for 
time period (as described above), country and donor type.  
All analyses were performed using SAS 9.3. 
RESULTS 
Incidence and prevalence  
A total of 342 patients with scleroderma were identified; comprising 0.14% of 236,082 
patients starting RRT between 2002 and 2013.  
The adjusted incidence of RRT for ESRD due to scleroderma between 2002 and 2013 
was 0.18 pmp, ranging from 0.0 to 0.25 pmp between regions/countries (Table 1). The 
adjusted incidence of RRT for ESRD due to scleroderma was 0.26 pmp in 2002 and 0.12 pmp 
in 2013 (Table 2). There was a trend towards a decline in the incidence pmp over time but this 
did not reach statistical significance (MPAC = -3.6; [95%CI: -7.9; 0.8]).  
During the study period, the adjusted prevalence of RRT for ESRD due to scleroderma 
varied between 0.73 and 0.95 pmp per year (Table 2) with a statistically significant increase 
in the prevalence pmp (MPAC = 2.0; [95%CI: 1.0; 2.9]). 
Patient characteristics 
Patients commencing RRT for ESRD due to scleroderma were significantly younger 
than patients (before matching) with other diagnoses (median age of 59.9 [Q1-Q3, 50.2-68.2] 
years for patients with scleroderma vs. 67.2 [Q1-Q3, 54.4-76.1] years for all non-scleroderma 
patients; P<0.001). The proportion of women within the scleroderma group was higher than 
that of non-scleroderma group (68.1% vs. 38.2%; P<0.001). 
The group characteristics for the first 90 days or beyond the first 90 days are displayed 
in Table 3 for patients initiating RRT for ESRD due to scleroderma and for the control 
groups, matched on age group and sex. The treatment modality at day 91 after the start of 
RRT was different in patients with scleroderma compared with the matched control groups, 
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with a higher percentage of HD in the scleroderma patients (Table 3; P≤0.01 for both 
comparisons).  
A higher number of deaths during the first 90 days on RRT was observed in the 
scleroderma patients compared with both matched control groups (12.6% vs. 3.9% and 4.0%, 
respectively, Table 3; P<0.001 for both comparisons).  
The percentage of patients who recovered from RRT dependence during the first 90 
days on RRT did not differ between the scleroderma patients and the matched control groups. 
However, a higher proportion of patients with scleroderma recovered from RRT dependence 
beyond this time period (7.6% vs. 0.7% and 2.0% in the matched control groups diabetes and 
other-PRDs, respectively; both P<0.001). In patients who recovered from RRT dependence, 
the time to recovery was longer in those with a diagnosis of scleroderma than in both matched 
control groups (median of 255.5 [Q1-Q3, 130-454] vs. 112.0 [Q1-Q3, 40.5-178] days 
(diabetes) and 167.5 [Q1-Q3, 60-353] days (other-PRDs); both P<0.05) . The vast majority of 
patients who recovered from RRT dependence were female; 80.8% in patients with 
scleroderma, 83.2% for the matched control group with diabetes mellitus (p<0.05) and 60.0% 
in the other-PRDs matched control group (p<0.001). Median age was significantly lower in 
patients with scleroderma who recovered from RRT dependence than in both matched control 
groups (median 52.1 [25th-75th percentile: 47.9-56.8] vs. 64.6 [54.8-71.7] (diabetes) and 60.6 
[50.4-66.3] (other-PRDs) (p<0.05).   
A total of 46 of the 342 (13.7%) scleroderma patients who started RRT between 2002 
and 2013 received a kidney transplant during the study period. This percentage was 18.7% for 
the control group diabetes mellitus and 27.1% for the control group other-PRDs (both 
p<0.001 in comparison with scleroderma patients). 
Patient survival on RRT  
Figure 1a depicts the 5-year patient survival on RRT after day 91 for patients who 
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started RRT for ESRD due to scleroderma (38.9%; 95% CI, 32.0% - 45.8%) and for the 
matched control groups diabetes mellitus (46.0% [95%CI: 43.9% - 48.0%]), and other-PRDs 
(63.6% [95% CI: 61.6% - 65.6%]).  
After adjustment for time period and country, the mortality from day 91 after the 
commencement of RRT was higher in patients with scleroderma than in both matched control 
groups (i.e. diabetes and other-PRDs, HR= 1.25 [95%CI: 1.05 – 1.48] and 2.00 [95%CI: 1.69-
2.39], respectively; Figure 2a).  
Patient and graft survival after kidney transplantation 
Of the 57 patients with scleroderma who received their first kidney transplant between 
2002 and 2013, the percentage of patients with a living donor transplant was 35.6% in the 
scleroderma group, and 17.8% and 29.8% in the matched control groups of diabetes and other-
PRDs, respectively.  
The median time on dialysis before receiving their first transplant was significantly 
greater in the patients with scleroderma (2.9; Q1-Q3, 1.6-4.7 years) compared with the 
matched control groups (diabetes: 1.6 years [0.8-2.9]; and other-PRDs: 1.6 years [0.5-3.6], 
both p<0.001). 
Figure 1b and 1c present the 5-year patient and graft survival after receiving a first 
kidney transplant, respectively, for patients with scleroderma (88.2% [95%CI: 75.3% - 
94.6%] and 72.4% [95%CI: 55.0% - 84.0%]) and for the matched control groups with 
diabetes mellitus (84.3% [95%CI: 80.5% - 87.4%] and 76.5% [95%CI: 72.2% - 80.3%]) and 
other-PRDs  patients (89.3% [95%CI: 86.0% - 91.8%] and 81.5% [95%CI: 77.6% - 84.8%]), 
matched on age group at kidney transplantation and sex.  
The risk of death for patients with scleroderma after kidney transplantation, adjusted 
for country, time period and donor type, did not differ from patients with diabetes or other-
PRDs  (Figure 2b). Similarly, graft survival adjusted for country, time period and donor type 
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did not differ between the patients with scleroderma and the matched control groups (Figure 
2c). 
Causes of death 
Table 4 shows the causes of death for patients who started RRT for ESRD due to 
scleroderma and for the matched control groups since day 91. Patients with scleroderma had 
fewer deaths due to cardiovascular events (particularly myocardial ischemia and cardiac 
arrest) compared with the matched control group of patients with diabetes. Compared with the 
matched control group of patients with non- other-PRDs, there were fewer deaths due to 
malignancy and cardiac arrest among the patients with scleroderma. Conversely, there were 
more deaths due to heart failure. A large proportion of deaths in the patients with scleroderma 
were reported as “miscellaneous” or unknown. 
DISCUSSION 
Systemic sclerosis is a very rare cause of ESRD, and as such analysis of this condition 
requires multi-centre, multi-national studies performed over a long period of time. This study 
describes the characteristics and outcomes of patients with scleroderma requiring RRT in a 
large European cohort. We found that the age and sex adjusted incidence of RRT for ESRD 
due to scleroderma between 2002 and 2013 was only 0.18 pmp. There was a trend towards a 
decline in the incidence over time but this did not reach statistical significance. Conversely 
the prevalence significantly increased over the time period from 0.80 pmp in 2002 to 0.89 
pmp in 2013. Furthermore, we observed that survival on RRT in patients with scleroderma 
was worse than in other causes of ESRD, whilst transplant recipients with scleroderma 
showed a similar survival to the control groups. 
Scleroderma is a rare disease with an estimated annual incidence of 10-20 pmp and a 
prevalence of about 30-300 pmp. The occurrence of scleroderma is presumed to be higher in 
North America or Australia than in Europe or Asia, even though epidemiological studies are 
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difficult to perform due to the low incidence and heterogeneity of the disease [18, 19]. The 
overall prevalence of scleroderma in the general population has been reported to increase, 
probably due to a greater awareness of the disease and improved patient survival [20], 
whereas there is in more recent studies some evidence suggesting a lower incidence of 
scleroderma renal crisis [1]. In keeping with this observation, we observed a non-statistically 
significant trend towards a decline in the incidence of RRT for ESRD due to scleroderma over 
time. However, as frequently seen in rare diseases with low numbers of patients, the number 
of cases in each year fluctuated. In Australia and New Zealand the incidence of patients with 
scleroderma requiring RRT for ESRD declined significantly between 2002 and 2013, from 
0.51 pmp to 0.18 pmp [21]. The prevalence of RRT for ESRD caused by scleroderma 
increased during the study period. This is most likely explained by the improved survival of 
patients with scleroderma receiving RRT.  
In this study, patients with scleroderma were less likely to be treated with PD than 
haemodialysis when compared with the matched control groups. This is in contrast to the data 
from the Australian and New Zealand registry where the use of PD was more common in 
patients with scleroderma than in patients with other causes of ESRD. However, PD is also a 
more frequent treatment option for ESRD in Australia than in Europe [11]. The choice of the 
“optimal” modality of RRT in patients with scleroderma is generally considered problematic 
[22].  
Scleroderma has long been recognized as a condition with a relatively high probability 
of renal recovery, even in patients requiring long-term dialysis [23]. This has important 
implications regarding the timing of kidney transplantation and some authors have 
recommended treating patients initially with dialysis for up to two years [13], whereas, for 
instance, the Canadian guidelines suggest that kidney transplantation could be considered in 
patients with scleroderma who have had quiescent disease for at least six months off cytotoxic 
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agents and have limited extra-renal disease [12]. Previous reports have described renal 
recovery in patients with scleroderma to be as high as 38% [1, 6]. However the Australian and 
New Zealand Registry, which includes patients with presumed ESRD [11], reported renal 
recovery at 10%, which is similar to the 7.6% observed in our study. The proportion of 
patients with presumed ESRD who recovered renal function in this study was higher in 
patients with ESRD secondary to scleroderma than in patients with other causes of ESRD. It 
has been previously noted that systemic autoimmune diseases commonly show higher 
recovery rates than other PRDs [24, 25]. Importantly, 25% of patients who recovered renal 
function in the current study discontinued dialysis after more than 15 months of RRT, 
supporting the recommendation of delaying kidney transplantation in these patients. This may 
explain why the time spent on dialysis before transplantation was longer in patients with 
scleroderma than in the matched control groups in our study. 
In previous studies exploring the survival of patients with scleroderma receiving RRT, 
a diagnosis of scleroderma mostly showed unfavourable outcomes [7, 11, 25] and was even 
identified as an independent predictor of death (HR of 2.47) [11]. Similarly, in the present 
study, we confirmed that both early and long-term mortality of patients with scleroderma 
receiving RRT remains high, and that the prognosis is worse than that of RRT patients with 
diabetes. Among the causes of death, cardiovascular events, especially ischemic heart disease, 
were much less common in patients with scleroderma than in patients with diabetes. 
Nevertheless, detailed evaluation of the causes of death was limited due to the high number of 
unknown or miscellaneous causes reported in the patients with scleroderma. 
Interestingly, patient and graft survival after kidney transplantation did not differ 
between patients with scleroderma and other PRDs. Given the poorer survival outcomes in 
patients with scleroderma, but similar post-transplant survival outcomes one must consider it 
likely that bias towards transplanting patients with scleroderma without major comorbidities 
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i.e. the healthiest patients exists. Furthermore given the small samples size one cannot rule out  
a possible type 2 error. Nevertheless, our findings support the use of kidney transplantation in 
at least some patients with scleroderma, preferably those without major extra-renal 
complications, although transplantation should be delayed due to the aforementioned chance 
of renal recovery. The 5-year graft survival rate of 72.4% in our study is greater than the 3-
year graft survival of 60.3% in the study by Gibney et al. [9], or the 5-year graft survival of 
56.7% in the study by Pham et al. [26], both using United States (US) data. Although direct 
comparison is hardly possible, it may suggest improving survival over time, even though 
there are known geographical differences, with a somewhat better graft survival in Europe 
than in the US [27].  
We are aware of the potential limitations of this study that include the registry-based 
nature of the data with a lack of detailed information regarding the disease course of 
individual patients, for example, disease duration prior to RRT, renal biopsy results, extent of 
extra-renal involvement, administered treatment, or disease recurrence after kidney 
transplantation. It should be noted that the patients included in this study originated from ten 
countries over a 12-year period. It is possible that country differences in the selection criteria 
for transplantation and a temporal effect may in part account for some of the differences we 
observed between the groups. As such there are known and unknown factors which we cannot 
take into account within this study. It is known that ESRD in some patients with scleroderma 
is not necessarily caused solely by scleroderma renal crisis, they may have for example 
normotensive renal crisis, penicillamine-associated nephropathy, scleroderma-associated 
vasculopathy, a mixed disease and overlap with for example, ANCA-associated vasculitis, in 
which case their renal survival and renal outcomes may be different [1, 28]. However, we 
were not able to distinguish such mixed causes of ESRD. Furthermore, on occasion it may be 
difficult to differentiate between acute cases of kidney failure requiring short-term (but 
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prolonged) dialysis from true ESRD in patients with a diagnosis of scleroderma. The view 
regarding such patients may differ between registries, some of which may not enter patients 
who recovered renal function as ESRD into the database, even though the time on dialysis 
exceeded three months which is typically the cut-off point for entering a patient requiring 
long-term RRT into the ESRD registry. In addition we do not have access to comorbidity data 
including diabetic status (beyond diabetes mellitus as a cause of ESRD). Having data on 
patient co-morbidities is required to further differentiate patients, for example, this 
information could have in part, accounted for the differences in transplantation rates and time 
to transplantation between patients with a diagnosis of scleroderma and the control groups. 
Nor do we have data on vascular access. Problems related to vascular access in patients with 
scleroderma may have contributed to differences in RRT outcomes when compared to control 
patients, which we are not aware of. On the other hand, the ERA-EDTA Registry provides a 
unique opportunity to analyse a large cohort of European patients with scleroderma receiving 
RRT and also allows for the direct comparison of patients with scleroderma with other causes 
of ESRD.  
In conclusion, we show that the overall survival of patients with scleroderma receiving 
RRT is worse than that of patients with ESRD due to diabetes or other PRDs. Although 
limited by a relatively low number of patients, our results suggest that kidney transplantation 
may be a sound therapeutic option in some patients with ESRD due to scleroderma, as graft 
and patient survival rates in this study were comparable with other non-diabetic causes of 
ESRD.  
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Table 1. Incidence of renal replacement therapy (RRT) for end-stage renal disease secondary to 
scleroderma, by country/region from 2002 to 2013 
 All RRT  Scleroderma 
Country  N N % N 
 pmp 
N 
pmp*† 
  Austria  14650 12 0.08 0.12 0.12 
  Belgium: Dutch-speaking 13968 16 0.11 0.22 0.20 
  Belgium: French-speaking 9943 11 0.11 0.20 0.23 
  Denmark 8431 17 0.20 0.26 0.25 
  Finland 5775 8 0.14 0.13 0.11 
  Greece 26181 31 0.12 0.23 0.21 
  Iceland     295  0    0   0    0 
  Netherlands 22131 37 0.17 0.19 0.19 
  Norway 5923 5 0.08 0.09 0.08 
  Spain: Andalusia  11817 11 0.09 0.11 0.12 
  Spain: Aragon 2031 3 0.15 0.19 0.18 
  Spain: Asturias 1772 2 0.11 0.15 0.14 
  Spain: Basque Country 3052 5 0.16 0.20 0.17 
  Spain: Cantabria  833 0   0    0    0 
  Spain: Castile and León 3654 8 0.22 0.27 0.23 
  Spain: Catalonia 12298 20 0.16 0.23 0.24 
  Spain: Valencian region 8582 7 0.08 0.12 0.12 
  Sweden 13640 19 0.14 0.17 0.17 
  United Kingdom 71106 130 0.18 0.19 0.19 
  All countries 236082 342 0.14 0.18 0.18 
 
*Pmp=per million population.  
†N pmp are adjusted for the age and sex distribution using the European Standard Population of 
2005 as reference. 
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Table 2. Incidence and prevalence of renal replacement therapy for end-stage renal disease 
secondary to scleroderma per million population by year from 2002 to 2013, and the mean 
percentage annual change (MPAC) with 95% confidence interval (95%CI) for all countries/regions 
combined, adjusted for age and sex using the European Standard Population of 2005 as a 
reference. 
 
Year 200
2 
200
3 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
MPAC 
(95%CI) 
Incidence 0.26 0.22 0.20 0.20 0.17 0.20 0.20 0.11 0.15 0.27 0.14 0.12 -3.6 (-7.9; 
0.8) 
Prevalenc
e 
0.80 0.75 0.73 0.81 0.81 0.90 0.89 0.88 0.85 0.95 0.95 0.89 2.0 (1.0; 2.9) 
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Table 3. Characteristics of patients starting RRT for ESRD according to primary cause of kidney disease 
(scleroderma, diabetes mellitus or other PRDs) and time since RRT.  
Group characteristics Scleroderma 
 
Control group 
DM*# 
Control group 
Other PRDs* 
First 90 days of commencing RRT  
Patients at day 1 of RRT, N 342 3420 3420 
Female at day 1 of RRT, % 68.1 68.1 68.1 
Median age at day 1 of RRT, years [25th-75th 
percentile] 
59.9 
[50.2-68.2] 
 
59.8 
[50.3-68.1] 
59.8 
[50.3-68.2] 
Patients who recovered from RRT 
dependence within 90 days, N [%]) 
3 (0.9) 21 (0.6) 38 (1.1) 
Patients who died within 90 days, N [%] 43 (12.6) 135 (3.9) 138 (4.0) 
Loss to follow-up/missing data within 90 days, 
N [%]) 
0 (0) 7 (0.2) 15 (0.4) 
Treatment discontinued/ limited care within 90 
days, N [%] 
0 (0) 4 (0.1) 
 
 
5 (0.2) 
Beyond 90 days of commencing RRT  
Patients at day 91 after start of RRT,  
N [% of number of patients at day 1]  
296 (86.5) 3253 (95.1) 3224 (94.3) 
Female at day 91 of RRT, % 67.2 67.9 68.4 
Median age at day 91 of RRT, years [25th-75th 
percentile] 
58.6 
[49.4-68.1] 
59.9 
[50.2-68.2] 
59.6 
[49.9-68.1] 
Treatment modality at day 91    
  Haemodialysis, % 83.4 75.9 70.4 
  Peritoneal dialysis, % 14.9 20.6 22.5 
  Transplantation, % 1.7 3.5 7.1 
Median time to recovery from RRT 
dependence, days [25th-75th percentile] 
255.5 [130.0-
454.0] 
112.0 [40.5-
178.0] 
167.5 [60.0-
353.0] 
*The matched-control groups were matched on day 1 of renal replacement therapy (RRT), based on age 
group and sex. 
# DM = diabetes mellitus as primary renal disease; the matched control groups did not include patients 
with scleroderma. 
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Table 4. Causes of death in patients starting renal replacement therapy (RRT) for end-stage renal disease 
secondary to scleroderma and the matched control groups since day 91  
 Scleroderma  
 
n=296 
Control group*  
DM 
n=3,253 
Control group*  
other-PRDs n= 3,224 
Number of deaths (%) 156 (52.7) 1,613 
(49.6) 
 1,134 
(35.2) 
 
Cause of death % %  P value# % P value# 
Cardiovascular disease 21.2 36.3 <0.001 23.8 0.5 
  Myocardial ischaemia/infarction 4.5 12.8 0.002 5.5 0.6 
  Heart failure 8.3 5.3 0.1 4.4 0.03 
  Cardiac arrest; other cause/unknown 3.9 12.0 0.002 9.1 0.03 
  Cerebrovascular accident 4.5 6.2 0.4 4.9 0.8 
Infection 14.1 17.3 0.3 15.4 0.7 
Suicide/refusal of dialysis 3.9 1.7 0.06 2.6 0.4 
Withdrawal from dialysis 5.8 5.8 0.9 5.6 0.9 
Cachexia 3.9 1.6 0.04 2.0 0.2 
Malignancy 1.9 3.8 0.2 10.4 <0.001 
Miscellaneous 19.2 12.7 0.02 16.3 0.4 
Unknown/unavailable/missing 30.1 20.8 0.007 23.9 0.09 
Percentages may not add up to 100% because of rounding off. DM = diabetes mellitus as primary renal 
disease. 
*Control groups are matched on 5-year age groups and sex; # comparison of control group with patients 
with scleroderma. The matched control groups did not include patients with scleroderma. 
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Legends to Figures 
 
Figure 1. Kaplan-Meier survival analyses. (a) Patient survival on renal replacement therapy (RRT) 
for end-stage renal disease secondary to scleroderma (n=296) from day 91, and for the matched 
control groups with either diabetes mellitus (DM; n=3253) as a primary renal disease or other-
PRDs (n=3224). Control groups are matched on 5-year age groups at the onset of RRT and sex. Median 
age was 59.9 years and 68.1% were female in the scleroderma group and in each matched control 
group. The matched control groups did not include patients with scleroderma. (B) Patient and (C) 
graft survival after kidney transplantation for end-stage renal disease secondary to scleroderma 
(n=57), and for the matched control groups with either DM as a primary renal disease or other-
PRDs (n=565 for each matched control group). Control groups are matched on 5-year age groups at 
the time of transplantation and sex. Median age was 49 years and 62.7% were female in the 
scleroderma group and in each matched control group. The matched control groups did not 
include patients with scleroderma.  
 
Figure 2. Hazard ratios (a) for death on RRT, (b) death after kidney transplantation, and (c) graft failure 
after kidney transplantation for patients with scleroderma versus the matched control groups, unadjusted 
and adjusted for time period, country, and (if applicable) donor type. Control groups with either diabetes 
mellitus (DM) as a primary renal disease or other-PRDs are matched on sex and 5-year age groups at (a) 
the onset of renal replacement therapy or (b-c) the time of transplantation. The scleroderma group and 
each matched control group had a median ages of (a) 59.9 and (b-c) 49 years, and (a) 68.1% and (b-c) 
62.7% were female. The matched control groups did not include patients with scleroderma.  
 
 
